1 citations
,
March 2025 in “Frontiers in Physiology” This study identified key genes linked to immune cells and potential therapeutic compounds for alopecia areata by evaluating upregulated genes from patient datasets, highlighting T and NK cell involvement in hair follicle attack and suggesting drug candidates through molecular docking and dynamics simulations.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, researchers used a computational drug repurposing approach to identify FDA-approved drugs Dutasteride and Solifenacin as potential inhibitors of Listeria monocytogenes via binding to the virulence factor regulator PrfA, suggesting they may offer new treatment strategies against multi-drug resistant strains.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.
2 citations
,
November 2025 in “British Journal of Pharmacology” In this study, researchers validated a computational workflow for repurposing non-antibacterial drugs as antibacterial agents and highlighted daprodustat, combined with an efflux pump inhibitor, as a promising strategy against bacterial pathogens.